secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001193125-24-256014
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Teva elects Chen Lichtenstein to board effective Dec 1, 2024
------------------------------------------------------------

- Chen Lichtenstein elected as independent director, effective Dec 1, 2024, until 2025 annual meeting.
- Lichtenstein was CFO of Syngenta Group (2020-2023) and previously CEO of ADAMA Ltd.
- He holds a Ph.D. in Business Administration from Stanford and multiple degrees from Hebrew University.
- Compensation will be the same as Teva's other non-executive directors.
- No material related-party transactions or family relationships with Teva executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312524256014/0001193125-24-256014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312524256014/d853506d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-256014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer